A detailed history of Black Rock Inc. transactions in Uni Qure N.V. stock. As of the latest transaction made, Black Rock Inc. holds 1,925,764 shares of QURE stock, worth $12.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,925,764
Previous 1,860,681 3.5%
Holding current value
$12.4 Million
Previous $9.68 Million 10.83%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$4.39 - $5.43 $285,714 - $353,400
65,083 Added 3.5%
1,925,764 $8.63 Million
Q1 2024

May 10, 2024

BUY
$4.82 - $6.93 $115,607 - $166,216
23,985 Added 1.31%
1,860,681 $9.68 Million
Q4 2023

Feb 13, 2024

BUY
$5.63 - $8.27 $593,852 - $872,319
105,480 Added 6.09%
1,836,696 $12.4 Million
Q3 2023

Nov 13, 2023

SELL
$6.71 - $11.83 $21.6 Million - $38 Million
-3,213,761 Reduced 64.99%
1,731,216 $11.6 Million
Q2 2023

Aug 11, 2023

BUY
$11.12 - $22.2 $275,831 - $550,671
24,805 Added 0.5%
4,944,977 $56.7 Million
Q1 2023

May 12, 2023

SELL
$18.7 - $23.07 $1.08 Million - $1.34 Million
-57,998 Reduced 1.17%
4,920,172 $99.1 Million
Q4 2022

Feb 13, 2023

BUY
$18.12 - $27.32 $1.44 Million - $2.17 Million
79,530 Added 1.62%
4,978,170 $113 Million
Q3 2022

Nov 14, 2022

BUY
$16.98 - $25.54 $10.2 Million - $15.3 Million
599,805 Added 13.95%
4,898,640 $91.9 Million
Q2 2022

Aug 12, 2022

SELL
$13.15 - $20.45 $892,898 - $1.39 Million
-67,901 Reduced 1.55%
4,298,835 $80.1 Million
Q1 2022

May 12, 2022

BUY
$14.54 - $21.5 $1.06 Million - $1.57 Million
72,931 Added 1.7%
4,366,736 $78.9 Million
Q4 2021

Feb 10, 2022

BUY
$20.24 - $36.01 $1.02 Million - $1.81 Million
50,307 Added 1.19%
4,293,805 $89.1 Million
Q3 2021

Nov 09, 2021

BUY
$26.01 - $38.22 $78 Million - $115 Million
2,998,944 Added 240.97%
4,243,498 $136 Million
Q2 2021

Aug 11, 2021

BUY
$29.97 - $37.17 $37.3 Million - $46.3 Million
1,244,554 New
1,244,554 $38.3 Million

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.